|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Bioregulatory Medicine Department of Neuropsychiatry |
Mishima Kazuo
|
|
|
Research Interests 【 display / non-display 】
-
Psychiatry
-
Chronobiology
-
精神神経科学／時間生物学/分子遺伝学/睡眠/加齢変化/精神薬理学的研究
Graduating School 【 display / non-display 】
-
-1987.03
Akita University Faculty of Medicine Graduated
Campus Career 【 display / non-display 】
-
2018.09-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Bioregulatory Medicine Professor
Research Areas 【 display / non-display 】
-
Life Science / Psychiatry
-
Life Science / Neuroscience-general
Research Achievements 【 display / non-display 】
-
Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan.
Masahiro Takeshima, Kazuhisa Yoshizawa, Masaya Ogasawara, Mizuki Kudo, Yu Itoh, Naoko Ayabe, Kazuo Mishima
JAMA network open 7 ( 4 ) e246865 2024.04 [Refereed]
Research paper (journal) Domestic Co-author
IMPORTANCE: Although insomnia guidelines recommend the use of several individual hypnotics, the most useful hypnotic for treating insomnia in a clinical setting remains unclear. OBJECTIVE: To determine which guideline-recommended hypnotics have lower risks of monotherapy failure and which hypnotics have a higher risk of long-term prescription for insomnia treatment. DESIGN, SETTING, AND PARTICIPANTS: This retrospective observational cohort study used data from the Japan Medical Data Center Claims Database from April 1, 2005, to March 31, 2021. Participants included adults whose first prescribed pharmaceutical treatment for insomnia was guideline-recommended hypnotic monotherapy. Data were analyzed from December 24, 2022, to September 26, 2023. EXPOSURES: Suvorexant, ramelteon, eszopiclone, zolpidem, and triazolam monotherapy. MAIN OUTCOMES AND MEASURES: The primary outcome was monotherapy failure, defined as a change in hypnotic or having an additional hypnotic prescribed for insomnia within 6 months of the first prescription of a guideline-recommended hypnotic monotherapy. The secondary outcome was monotherapy discontinuation, defined as no prescription of any hypnotic for 2 consecutive months within 6 months after prescribing a guideline-recommended hypnotic in patients for whom monotherapy did not fail. Monotherapy failure and discontinuation were compared using Cox proportional hazards and logistic regression models, respectively. RESULTS: The study included 239 568 adults (median age, 45 [IQR, 34-55] years; 50.2% women) whose first prescription for insomnia was guideline-recommended hypnotic monotherapy. During the 6-month follow-up period, 24 778 patients (10.3%) experienced failure of monotherapy with a guideline-recommended hypnotic. In comparison with eszopiclone, there were more cases of monotherapy failure for ramelteon (adjusted hazard ratio [AHR], 1.23 [95% CI], 1.17-1.30; P < .001), fewer cases for zolpidem (AHR, 0.84 [95% CI, 0.81-0.87]; P < .001) and triazolam (AHR, 0.82 [95% CI, 0.78-0.87]; P < .001), and no significant difference between suvorexant and eszopiclone. Among those without monotherapy failure, monotherapy was discontinued in 84.6% of patients, with more discontinuations for ramelteon (adjusted odds ratio [AOR], 1.31 [95% CI, 1.24-1.40]; P < .001) and suvorexant (AOR, 1.20 [95% CI, 1.15-1.26]; P < .001) than for eszopiclone and no significant difference between zolpidem or triazolam and eszopiclone. CONCLUSIONS AND RELEVANCE: Due to uncontrolled confounding factors in this cohort study, no conclusions regarding the pharmacologic properties of guideline-recommended hypnotics can be drawn based on these results. Further studies accounting for confounding factors, including diagnoses of chronic vs acute insomnia disorder, insomnia and psychiatric symptom severity, and physician attitudes toward hypnotic prescription, are needed.
-
Impact of aripiprazole discontinuation in remitted major depressive disorder: a randomized placebo-controlled trial.
Masahiro Takeshima, Akise Umakoshi, Yuki Omori, Kazuhisa Yoshizawa, Masaya Ogasawara, Mizuki Kudo, Yu Itoh, Naoko Ayabe, Kazuo Mishima
Psychopharmacology 2024.03 [Refereed]
Research paper (journal) Domestic Co-author
RATIONALE: The efficacy and safety of antidepressant augmentation therapy with aripiprazole (AATA) has been established; however, the ongoing effects of continuing aripiprazole after remission remain unclear because no studies have examined this issue. OBJECTIVES: We aimed to explore the effect of AATA discontinuation on the major depressive disorder (MDD) recurrence risk in patients with remitted MDD after AATA. METHODS: This 24-week, multicenter, placebo-controlled, double-blind, randomized trial evaluated recurrence risk in patients with MDD who achieved remission with AATA. Differences in MDD recurrence, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, between the two groups were compared using survival analysis. The differences in depressive symptom severity and social functioning between the two groups were compared using a mixed model with repeated measures. Extrapyramidal symptoms and akathisia were also assessed. RESULTS: Twenty-three participants were randomized and treated. Two patients in each group experienced recurrence during the study. Kaplan-Meier analysis with Log-rank comparison showed no difference in recurrence between groups (p = 0.642). No significant difference in interactions between group and period was observed in the 17-item Hamilton depression rating scale (p = 0.492) or the Social and Occupational Functioning Assessment Scale (p = 0.638). No patients developed extrapyramidal symptoms or akathisia. CONCLUSIONS: Definitive conclusions could not be drawn owing to the small sample size. This study represents a starting point for investigating the safety of aripiprazole discontinuation on recurrence in patients with MDD who have achieved remission with AATA. Future studies with appropriate sample sizes calculated based on this study are needed.
-
Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia
Aoki, Y. Takaesu, Y. Matsui, K. Tokumasu, T. Tani, H. Takekita, Y. Kanazawa, T. Kishimoto, T. Tarutani, S. Hashimoto, N. Takeuchi, H. Mishima, K. Inada, K.
Neuropsychopharmacol Rep ( Wiley ) 2023.07 [Refereed]
Research paper (journal) Domestic Co-author
-
Clinical practice for unspecified anxiety disorder in primary care
Sakurai, H. Takeshima, M. Inada, K. Aoki, Y. Ie, K. Kise, M. Yoshida, E. Tsuboi, T. Yamada, H. Hori, H. Inada, Y. Shimizu, E. Mishima, K. Watanabe, K. Takaesu, Y.
Psychiatry and Clinical Neurosciences Reports ( Wiley ) 2 ( 3 ) 2023.06 [Refereed]
Research paper (journal) Domestic Co-author
-
The Relationship between Insomnia and Lifestyle-Related Diseases among Japanese Male Truck Drivers.
Tomoka Ando, Takashi Miyachi, Yuta Sugano, Makoto Kamatsuka, Kazuo Mishima, Kyoko Nomura
The Tohoku journal of experimental medicine 2023.06 [Refereed]
Research paper (journal) Domestic Co-author
-
岸太郎, 江角悟, 大矢一登, 奥谷理, 佐久間健二, 野村郁雄, 橋本保彦, 波多野正和, 波多野正和, 松井佑樹, 松田勇紀, 三宅誕実, 三島和夫, 岩田仲生
臨床精神薬理 24 ( 9 ) 937 - 942 2021
Introduction and explanation (scientific journal) Domestic Co-author
-
How to use, reduce, and stop hypnotics after insomnia remission
22 ( 8 ) 815 - 820 2019.08
Introduction and explanation (scientific journal)
-
Non-visual Effects of Light : Influence on alertness and cognitive function
61 ( 8 ) 883 - 889 2019.08
Introduction and explanation (scientific journal)
-
【知っておきたい器質性・症状性・薬剤性の精神障害:Update】抗NMDA受容体脳炎
筒井 幸, 馬越 秋瀬, 神林 崇, 田中 惠子, 清水 徹男, 三島 和夫
臨床精神医学 ( (株)アークメディア ) 48 ( 1 ) 11 - 16 2019.01
Introduction and explanation (scientific journal)
-
Clinical Significance of the Clinical Practice Guideline for Proper Use and Cessation of Hypnotics
60 ( 9 ) 949 - 956 2018.09
Introduction and explanation (scientific journal) Single author
-
Association of stay-home order during COVID-19 pandemic with depressive symptoms and suicide-related ideation in university students in Japan
野村恭子, 南園佐知子, 前田恵理, KIM Roseline, 岩田豊人, 平山純子, 尾野恭一, 伏見雅人, 後藤猛, 三島和夫, 山本文雄
日本心身医学会総会ならびに学術講演会抄録集 62nd (CD-ROM) 2021
Summary of the papers read (national conference and other science council) Domestic Co-author
-
睡眠・覚醒相後退障害に対する心理社会支援プログラム開発の試み
綾部直子, 吉村道孝, 栗山健一, 三島和夫, 三島和夫
日本睡眠環境学会学術大会抄録集 28th 106 2019.09
Summary of the papers read (national conference and other science council)
-
精神科学と神経免疫学のクロストーク 精神科領域からみた自己免疫性辺縁系脳炎
筒井 幸, 馬越 秋瀬, 奥口 悠紀, 神林 崇, 田中 惠子, 清水 徹男, 三島 和夫
精神神経学雑誌 ( (公社)日本精神神経学会 ) ( 2019特別号 ) S340 - S340 2019.06
Summary of the papers read (national conference and other science council)
-
北村真吾, 榎本みのり, 三井寺浩幸, 立森久照, 三島和夫
国立精神・神経医療研究センター精神保健研究所年報 ( 30 ) 235 2017.10
Summary of the papers read (national conference and other science council)
-
多施設共同RCTによる不眠症に対する認知行動療法(Cognitive Behavioral Therapy for Insomnia:CBT‐I)の有効性
綾部直子, 鈴木みのり, 立森久照, 北村真吾, 亀井雄一, 三島和夫
国立精神・神経医療研究センター精神保健研究所年報 ( 30 ) 235 2017.10
Summary of the papers read (national conference and other science council)
◆Original paper【 display / non-display 】
◆Introduction and explanation【 display / non-display 】
◆Other【 display / non-display 】
Books 【 display / non-display 】
-
Tasman’s Psychiatry
三島和夫
Springer 2023.01
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Scientific Research(B)
Project Year： 2023.04 - Now
-
Construction and feature analysis of a model for predicting clinical outcomes of psychiatric disorders using sleep, behavioral, and physiological parameters.
Grant-in-Aid for Scientific Research(B)
Project Year： 2022.04 - 2025.03
-
Grant-in-Aid for Scientific Research(B)
Project Year： 2019.04 - 2022.03
-
Grant-in-Aid for Scientific Research(B)
Project Year： 2016.04 - 2019.03
-
Grant-in-Aid for Scientific Research(S)
Project Year： 2015.04 - 2016.03
Academic Activity 【 display / non-display 】
-
2020.10-Now
-
2020.10-Now
-
2020.03-Now